Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer

Sun Yat-sen University

Status: Completed

Conditions: Ovarian Cancer; AKI - Acute Kidney Injury

Treatments: Procedure: Hyperthermic intraperitoneal chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06697613

SYSKY-2024-959-01

Details and patient eligibility

About

Ovarian cancer is the most lethal malignant tumor of the female reproductive system. Cytoreduction surgery(CRS) combined with chemotherapy is the primary method for treating ovarian cancer, and complete tumor resection is an important means to improve prognosis. It has been demonstrated that the use of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) following CRS can significantly improve the prognosis of some patients with ovarian cancer. However, HIPEC with cisplatin can lead to acute kidney injury (AKI), a serious complication that can seriously affect the patient's short- and long-term prognosis. NCCN guidelines recommend the use of sodium thiosulfate in all patients receiving HIPEC. This study intends to retrospectively collect clinical characteristics of patients to establish a prediction model for kidney injury, with a view to screening those at high risk of kidney injury for use of sodium thiosulfate for nephrotoxicity rescue in cisplatin HIPEC.

Enrollment: 150 patients

Sex: Female

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who received HIPEC with cisplatin following cytoreductive surgery.
• Patients diagnosed with ovarian cancer pathologically.
• FIGO stage III-IV.

Exclusion criteria

• Use of renal protective drugs such as sodium perthiosulfate.
• Any grade of chronic or acute renal disease or other serious complications existed before HIPEC.
• Patients with single kidney.

Trial design

150 participants in 1 patient group

CRS-HIPEC

Treatment:

Procedure: Hyperthermic intraperitoneal chemotherapy